Vaxxinity will continue developing vaccines for COVID-19 and neurological disorders, including Alzheimer's and Parkinson's diseases, as well as prevalent chronic disorders such as migraine and hypercholesterolemia.

The lead candidate in Vaxxinity's pipeline is UB-612, a vaccine candidate to fight SARS-CoV-2 that has shown some promise in phase I trials. The candidate uses COVAXX's proprietary synthetic peptide technology and is a multitope protein/peptide-based vaccine designed to activate B- and T-cell immune responses against SARS-CoV-2.

Vaxxinity's shipping partner, Maersk, will provide the capabilities to deliver hundreds of millions of UB-612 doses worldwide, using existing infrastructure.

COVAXX and United Neuroscience are now wholly owned subsidiaries of Vaxxinity. Lou Reese, executive chairman of COVAXX, has been appointed executive chairman of Vaxxinity, while Mei Mei Hu, CEO of COVAXX, has been appointed CEO of Vaxxinity.